ORIC PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ORIC PHARMACEUTICALS, INC. (ORIC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 154.20 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 40.11K shares, a 7.89% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 114.09K shares, a 1815.87% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 131.10K shares, a 2688.68% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 311.06K shares, a 395.88% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 491.66K shares, a 104.38% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 240.56K shares, a 263.90% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 66.11K shares, a 98.64% decline from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 4.86M shares, a 1755.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 40.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 154.20K shares 10-Q · filed 2026-08-03 | 285.30K shares derived: sum of 3 quarters · filed 2026-08-03 | 596.36K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 114.09K shares 10-Q · filed 2026-05-04 | 245.19K shares derived: sum of 2 quarters · filed 2026-05-04 | 556.24K shares derived: sum of 3 quarters · filed 2026-05-04 | 599.79K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 131.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 442.15K shares derived: sum of 2 quarters · filed 2026-02-23 | 485.70K shares derived: sum of 3 quarters · filed 2026-02-23 | 491.66K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 311.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 354.61K shares derived: sum of 2 quarters · filed 2025-11-13 | 360.56K shares 10-Q · filed 2025-11-13 | 365.26K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 43.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 49.50K shares 10-Q · filed 2025-08-12 | 54.20K shares derived: sum of 3 quarters · filed 2025-08-12 | 116.93K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 5.96K shares 10-Q · filed 2025-05-05 | 10.66K shares derived: sum of 2 quarters · filed 2025-05-05 | 73.38K shares derived: sum of 3 quarters · filed 2025-05-05 | 123.49K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 4.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | 67.43K shares derived: sum of 2 quarters · filed 2025-02-18 | 117.53K shares derived: sum of 3 quarters · filed 2025-02-18 | 240.56K shares 10-K · filed 2025-02-18 |
| 2024-09-30 | 62.73K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 112.83K shares derived: sum of 2 quarters · filed 2024-11-12 | 235.85K shares 10-Q · filed 2024-11-12 | 258.51K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 50.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 173.13K shares 10-Q · filed 2024-08-12 | 195.79K shares derived: sum of 3 quarters · filed 2024-08-12 | 217.36K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 123.03K shares 10-Q · filed 2024-05-06 | 145.69K shares derived: sum of 2 quarters · filed 2024-05-06 | 167.26K shares derived: sum of 3 quarters · filed 2024-05-06 | 176.48K shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | 22.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 44.24K shares derived: sum of 2 quarters · filed 2024-03-11 | 53.46K shares derived: sum of 3 quarters · filed 2024-03-11 | 66.11K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 21.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 30.80K shares derived: sum of 2 quarters · filed 2023-11-06 | 43.45K shares 10-Q · filed 2023-11-06 | 91.72K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 9.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 21.87K shares 10-Q · filed 2023-08-10 | 70.15K shares derived: sum of 3 quarters · filed 2023-08-10 | 4.56M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 12.65K shares 10-Q · filed 2023-05-08 | 60.92K shares derived: sum of 2 quarters · filed 2023-05-08 | 4.55M shares derived: sum of 3 quarters · filed 2023-05-08 | 4.71M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 48.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 4.54M shares derived: sum of 2 quarters · filed 2023-03-16 | 4.70M shares derived: sum of 3 quarters · filed 2023-03-16 | 4.86M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 4.49M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 4.65M shares derived: sum of 2 quarters · filed 2022-11-07 | 4.82M shares 10-Q · filed 2022-11-07 | 4.87M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 155.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 324.39K shares 10-Q · filed 2022-08-11 | 377.33K shares derived: sum of 3 quarters · filed 2022-08-11 | 512.95K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 168.75K shares 10-Q · filed 2022-05-09 | 221.69K shares derived: sum of 2 quarters · filed 2022-05-09 | 357.31K shares derived: sum of 3 quarters · filed 2022-05-09 | 414.79K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 52.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 188.56K shares derived: sum of 2 quarters · filed 2022-03-21 | 246.04K shares derived: sum of 3 quarters · filed 2022-03-21 | 262.24K shares 10-K · filed 2022-03-21 |
| 2021-09-30 | 135.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 193.10K shares derived: sum of 2 quarters · filed 2021-11-08 | 209.30K shares 10-Q · filed 2021-11-08 | 274.73K shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 57.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 73.68K shares 10-Q · filed 2021-08-10 | 139.11K shares derived: sum of 3 quarters · filed 2021-08-10 | 193.27K shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 16.20K shares 10-Q · filed 2021-05-06 | 81.63K shares derived: sum of 2 quarters · filed 2021-05-06 | 135.79K shares derived: sum of 3 quarters · filed 2021-05-06 | 174.73K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 65.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | 119.59K shares derived: sum of 2 quarters · filed 2021-03-23 | 158.53K shares derived: sum of 3 quarters · filed 2021-03-23 | 169.58K shares 10-K · filed 2021-03-23 |
| 2020-09-30 | 54.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 93.10K shares derived: sum of 2 quarters · filed 2020-11-05 | 104.16K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 38.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | 49.99K shares 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | 11.05K shares 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |